Non-IgG antibodies (particularly IgA subclass) as critical components of immune responses have gained significant importance in diagnostic and therapeutic applications for Vibrio cholerae infection. As a long-term pioneer as well as the market leader in the field of therapeutic antibody development, Creative Biolabs has successfully established and commercialized advanced platforms for non-IgG therapeutic antibody research. We are professional in providing one-stop non-IgG development services, including antibody production, purification, modification, etc., to help you get milestone success. IgA is one important class of therapeutic antibodies that we provide as promising treatments for human Vibrio cholerae infection.
Brief Introduction of Vibrio Cholerae Infection
Cholera is an intestinal infection that causes severe watery diarrhea, which may lead to dehydration and even death if untreated. The causative agent of cholera is Vibrio cholerae (V. cholerae), a Gram-negative, comma-shaped bacterium. It is a facultative pathogen that has both human and environmental stages in its life cycle. V. cholerae is differentiated serologically by the O antigen of its lipopolysaccharide (LPS), among which, O1 and O139 have been reported to cause epidemic cholera, whereas non-O1 and non-O139 V. cholerae are known to cause sporadic diarrhea and extraintestinal infections. V. cholerae can be transmitted after consuming contaminated water and food or through the fecal-oral spread, and both host genetic and nutritional factors affect susceptibility to cholera. Currently, antibiotic therapy can shorten the duration of diarrhea, but excessive use has contributed to the emergence of antibiotic resistance in V. cholerae. Therefore, it is urgent to develop effective therapies or innovative drugs with small side effects for cholera.
IgA Antibodies for Vibrio Cholerae Infection
Antigen-specific secretory IgA (SIgA), produced by mucosal immunity, contributes to the first line of specific defense against Vibrio cholerae infection. IgA antibodies directed against cholera toxin (CT) are thought to be important in resistance to oral challenge with virulent Vibrio cholerae. SIgA is solely responsible for antibody-mediated, cross-protective, long-term immunity against CT-induced diarrhea. In addition, IgA directed against the B subunit of CT can effectively block CT action on polarized enterocytes in vitro by sterically inhibiting toxin binding to apical cell surfaces. IgA is thought to play a role in limiting the duration of the V. cholerae infection and to be important in host resistance to subsequent reinfection. IgA currently can be considered as a sensitive immune-molecuele against V. cholerae infection and may be useful to the development of anti-cholera vaccine.
Fig.1 Synopses of the structural basis for the excellent anti-microbial binding properties of secretory IgA (SIgA). (Brandtzaeg, 2013)
Why Choose Us?
- One-stop and fully customizable experimental design;
- High accuracy and repeatability can help you save time and cost;
- High-quality products with stronger affinity and enhanced neutralizing activity;
- Competitive price and best after-sale service.
As one pioneer in the non-IgG therapeutic antibodies research, Creative Biolabs is armed with first-in-class technologies and professional teams to perform a wide range of non-IgG antibodies development services to meet clients' demands. We can currently provide one-stop, customized non-IgG antibody services and a wide spectrum of non-IgG antibody products for various applications. The efficiency and quality of our exhaustive service have always been satisfying clients with highly reproducible and reliable results.
For more detailed information, please do not hesitate to contact us or directly send us an inquiry.
Reference
- Brandtzaeg, P. Secretory IgA: designed for anti-microbial defense. Frontiers in immunology. 2013, 4: 222.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
